×
About 1,992 results
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
https://jnccn.org/view/journals/jnccn/17/11/article-p1278.xml
JNCCN Motzer RJ, et al.

Nov 13th, 2019 - The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non–clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-lin...

Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies
https://www.mdpi.com/2072-6694/11/8/1174
Cancers Petrelli, F. et. al.

Jul 30th, 2019 - The association between antibiotic use and risk of cancer development is unclear, and clinical trials are lacking. We performed a systematic review and meta-analysis of observational studies to assess the association between antibiotic use and risk of cancer. PubMed, the Cochrane Library and EMBASE were searched from inception to 24 February 2019 for studies reporting antibiotic use and subsequ...

Pfizer Receives U.S. Fda Approval For Its Oncology Biosimilar, Zirabev™ (Bevacizumab-bvzr)
https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_u_s_fda_approval_for_its_oncology_biosimilar_zirabev_bevacizumab_bvzr

Jun 26th, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration(FDA) has approved ZIRABEV™ (bevacizumab-bvzr), a biosimilar to Avastin® (bevacizumab),1 for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic ren...

FDA Approves Bavencio® (Avelumab) Plus Inlyta® (Axitinib) Combination For Patients With Advanced Renal Cell Carcinoma
https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_bavencio_avelumab_plus_inlyta_axitinib_combination_for_patients_with_advanced_renal_cell_carcinoma

May 13th, 2019 - Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) in combination with INLYTA® (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). This is the first FDA approval for ...

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.
https://meetinglibrary.asco.org/record/170343/abstract

Feb 15th, 2019 - A phase 1b study of pembro (anti–PD-1) plus axi (VEGFR-TKI) showed promising antitumor activity and manageable safety in patients (pts) with previously untreated mRCC. The global, open-label, phase 3 KEYNOTE-426 study assessed the efficacy and safety of pembro + axi vs sunitinib as first-line therapy for mRCC (NCT02853331).

Pivotal Phase Iii Data For Bavencio® (Avelumab) Plus Inlyta® (Axitinib) In Advanced Renal Cell Carcinoma Published In The New England Journal Of Medicine
https://www.pfizer.com/news/press-release/press-release-detail/pivotal_phase_iii_data_for_bavencio_avelumab_plus_inlyta_axitinib_in_advanced_renal_cell_carcinoma_published_in_the_new_england_journal_of_medicine

Feb 15th, 2019 - JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression US FDA has granted Priority Review to BAVENCIO plus INLYTA for patients with advanced renal cell carcinoma Data at 2019 Genitourinary Cancers Symposium reinforce consistency of PFS and ORR benefits across broad population of patients with advanced R...

FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
https://www.pfizer.com/news/press-release/press-release-detail/fda_accepts_sbla_and_grants_priority_review_for_bavencio_avelumab_plus_inlyta_axitinib_for_the_treatment_of_advanced_renal_cell_carcinoma

Feb 10th, 2019 - EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) in combination with INLYTA® (axitinib)* for patients with advanced renal cell carcinoma (RCC). ...

Tivozanib Prolongs PFS in Refractory Kidney Cancer
https://www.medscape.com/viewarticle/922857

Dec 19th, 2019 - NEW YORK (Reuters Health) - In patients with refractory renal cell carcinoma (RCC), third- or fourth-line tivozanib improved progression-free survival and was better tolerated than sorafenib, a pivotal study shows. "The study adds a novel option for patients with previously treated RCC," Dr. Brian Rini of Cleveland Clinic in Ohio told Reuters Health by email. "If FDA approved, this would repres...

RCC: Tivozanib beats sorafenib in later lines
https://www.mdedge.com/hematology-oncology/article/214563/renal-cell-carcinoma/rcc-tivozanib-beats-sorafenib-later-lines?channel=39313
Will Pass

Dec 19th, 2019 - For third- or fourth-line treatment of metastatic renal cell carcinoma, the vascular epidermal growth factor receptor (VEGFR) tyrosine kinase inhibitor tivozanib may offer better progression-free survival than sorafenib, another VEGFR inhibitor, based on results from the TIVO-3 trial. Susan London/MDedge News Dr.

Atezolizumab/bevacizumab may offer benefit to patients with RCC
https://www.mdedge.com/fedprac/article/213063/renal-cell-carcinoma/atezolizumab/bevacizumab-may-offer-benefit-patients-rcc?channel=112
Michele G. Sullivan

Nov 25th, 2019 - The combination of atezolizumab plus bevacizumab may offer some benefit to patients with advanced renal cell carcinoma, especially those who are positive for programmed death-ligand 1 (PD-L1), investigators report. The overall response rate (ORR) among such patients was 60%, compared with 19% in PD-L1–negative patients, Bradley A.

Promising Biomarkers for Diabetic Nephropathy
https://www.medscape.com/viewarticle/920689

Nov 11th, 2019 - We live in an age of "big data." One could argue that nephrology was at the forefront of such analyses with early trials using USRDS and DOPPS data. Proteomic and metabolomic studies are representative of modern-day big-data analyses and distinct from databases such as USRDS and DOPPS. Traditional databases include data from a large number of patients over an increasing period of time, but prot...

Terlipressin reversed hepatorenal syndrome in large prospective study
https://www.mdedge.com/internalmedicine/article/211366/hepatology/terlipressin-reversed-hepatorenal-syndrome-large?channel=53
Andrew D. Bowser

Nov 8th, 2019 - BOSTON – Terlipressin, an investigational vasopressin analogue, improved renal function and reversed hepatorenal syndrome type 1 (HRS-1) among patients with progressive advanced liver disease in a randomized trial, according to investigators. Compared with albumin alone, terlipressin plus albumin significantly reversed worsening of renal function in cirrhotic patients, including those meeting s.

Sunitinib for mRCC: Real-world experience differs somewhat
https://www.mdedge.com/hematology-oncology/article/211828/renal-cell-carcinoma/sunitinib-mrcc-real-world-experience-differs?channel=39313
Susan London

Nov 7th, 2019 - First-line sunitinib therapy for metastatic renal cell carcinoma (mRCC) has somewhat differing effectiveness and safety when used in real-world practice, compared with clinical trials, suggests the OSSMAR multicenter retrospective cohort study. Investigators led by Marwan Ghosn, MD, Hotel-Dieu de France University Hospital and Saint Joseph University, Beirut, Lebanon, analyzed outcomes among 28.

Ezrin negativity predicts poor prognosis in clear cell RCC
https://www.mdedge.com/hematology-oncology/article/211337/renal-cell-carcinoma/ezrin-negativity-predicts-poor-prognosis?channel=31848
Susan London

Oct 31st, 2019 - Patients whose clear cell renal cell carcinoma (RCC) tumors lack the cytoskeleton linker protein ezrin have a poorer prognosis, finds a single-center retrospective cohort study. The number of small renal masses discovered incidentally is rising, and some of these tumors can or must be treated less aggressively, according to lead investigator Marcos Vinicius O.

Poor Evidence Underpins Treatments for Hepatorenal Syndrome
https://www.medscape.com/viewarticle/920488

Oct 29th, 2019 - NEW YORK (Reuters Health) - Because almost all studies of treatments for hepatorenal syndrome (HRS) are flawed, one cannot be recommended over another, a systematic review and meta-analysis concludes. "I am surprised by the lack of good quality evidence to treat a condition that carries such a high risk of death," Dr. Kurinchi Selvan Gurusamy of University College London told Reuters Health by ...

Renal Cell Carcinoma: 5 Things to Know
https://www.medscape.com/viewarticle/920324

Oct 24th, 2019 - Renal cell carcinoma (RCC) is among the 10 most common cancers worldwide, accounting for approximately 2% of all cancer diagnosed.[1] As such, there is considerable research attention given to addressing RCC and its various histologic and molecular subtypes. Here are five things that every physician treating RCC should know about the latest data regarding its epidemiology, contributing risk fac...

Immunotherapy enables nephrectomy with good outcomes in advanced RCC
https://www.mdedge.com/hematology-oncology/article/210508/renal-cell-carcinoma/immunotherapy-enables-nephrectomy-good?channel=39313
Susan London

Oct 21st, 2019 - Some patients with advanced renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICIs) can safely undergo nephrectomy and experience favorable surgical outcomes and pathologic responses, a cohort study suggests. “The introduction of several novel classes of systemic therapies, including targeted therapies and most recently ICI, has revolutionized the management of metastatic RC.

Federal Health Care Cancer Data Trends 2019
https://www.mdedge.com/fedprac/article/209596/federal-health-care-cancer-data-trends-2019?channel=167

Oct 7th, 2019 - Click here to access Federal Health Care Cancer Data Trends 2019 Table of Contents Introduction Cancer in the VA: The Big Picture Hepatocellular Carcinoma Prostate Cancer Multiple Myeloma Lung Cancer in the VA at a National Level Lung Cancer – Regional Snapshot: Kansas City VA Colorectal Cancer Leukemias Lymphomas Renal Cell Carcinoma Bladder Cancer Afterword.

No difference between ipilimumab/nivolumab combo and immunotherapy plus VEGF for metastatic RCC
https://www.mdedge.com/hematology-oncology/article/209245/renal-cell-carcinoma/no-difference-between-ipilimumab/nivolumab?channel=214
Michele G. Sullivan

Oct 2nd, 2019 - There is no significant difference in response or survival rates between the combination of ipilimumab/nivolumab (ipi-nivo) and immuno-oncology plus vascular endothelial growth factor inhibition (IOVE) for patients with metastatic renal cell carcinoma. Therefore, the treatment should probably be directed by patient preferences, among other things, Shaan Dudani, MD, and colleagues wrote in Europ.

Canagliflozin OK'd for Preventing HF Hospitalization in T2D
https://www.medpagetoday.com/primarycare/diabetes/82473

Sep 30th, 2019 - WASHINGTON -- In another label expansion, the FDA approved new cardiovascular and renal prevention indications for canagliflozin (Invokana), according to a statement from the Janssen unit of Johnson & Johnson. The SGLT-2 inhibitor is now indicated for preventing end-stage kidney disease, worsening renal impairment, cardiovascular death, hospitalization for heart failure, and diabetic nephropath...